Search

The potential of immunotherapy as a treatment method for cancer is obvious based on the significant clinical response of a significant number of patients, mainly to chimeric antigen receptor-expressing pericyte transfer using transgenic autologous T cells. Nevertheless, the vast majority of malignant solid tumors do not respond specifically to CAR-T cell injections such as breast, colon and lung cancers. Suboptimal outcomes have been linked to lower expansion. They are also related to the durability of adoptively transferred CAR-T cells, antigen-negative relapses, and impairment by an immunosuppressive tumor microenvironment in a series of clinical trials. The current status of CAR-T cell therapy of solid cancers is discussed. At the same time, this paper also discusses the barriers and how to overcome these obstacles so that CAR-T immunotherapy can be one of the treatment methods for malignant solid tumors. [ABSTRACT FROM AUTHOR]

Tumor microenvironment (TME) plays a key role in tumor immune escape. PD-1/PD-L1 signal transduction pathway can achieve tumor immune escape by enhancing tumor cell immune tolerance and inhibiting the activation of T lymphocytes. In recent years, immunosuppression, as one of the many mechanisms of tumor immune escape, has also become a research hotspo. The optimized CAR-T cells released immunosuppression by secreting antibodies against checkpoint inhibitors. Therefore, CAR-T therapy targeting tumor micro environment and PD-1/PD-L1 pathway are important methods for cancer treatment. This paper summarizes the role of PD-1/PD-L1 signaling pathway in mediating tumor escape in tumor microenvironment, and briefly introduces CAR-T immunotherapy and its TME-related targets. [ABSTRACT FROM AUTHOR]